ReviewJournal of thoracic disease2019
Indications for lung transplant referral and listing.
Review in Journal of thoracic disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Influence of Extended Itraconazole Antifungal Prophylaxis on the Development of Fungal Infections After Lung Transplant.Journal of transplantation · 2026Article
- Optimizing patient outcomes in interstitial lung disease through pre- and post-transplant management strategies.World journal of transplantation · 2025Review
- Racial disparities in lung function by pulmonary function testing among lung transplant candidates and race-specific reference equations.JHLT open · 2025Article
- Lung Transplantation in the United States for COVID-19 Related Lung Disease During the Pandemic.Lung · 2024Article
- Use of Race-Specific Equations in Pulmonary Function Tests Impedes Potential Eligibility for Care and Treatment of Pulmonary Fibrosis.Annals of the American Thoracic Society · 2024Observational
- Implications of Race Adjustment in Lung-Function Equations.The New England journal of medicine · 2024Article
- Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment.Frontiers in medicine · 2024Review
- A primer for the student joining the general thoracic surgery service tomorrow: Primer 2 of 7.JTCVS open · 2023Article
- Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement.American journal of respiratory and critical care medicine · 2023Article
- Lung Transplantation in India: a Brief Review, Landmarks, Indian Scenario, and our Experience.The Indian journal of surgery · 2023Article
- Reply to Townsend and Cowl.American journal of respiratory and critical care medicine · 2022Article
- Addressing Race in Pulmonary Function Testing by Aligning Intent and Evidence With Practice and Perception.Chest · 2022Review
- Waiting time and mortality rate on lung transplant candidates in Japan: a single-center retrospective cohort study.BMC pulmonary medicine · 2021Article
- Lung Transplantation and the Era of the Sensitized Patient.Frontiers in immunology · 2021Review
- Transplantation for work-related lung disease in the USA.Occupational and environmental medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung transplantation is a valuable therapeutic option for many patients with severe lung disease who have exhausted other medical or surgical therapies. However, since lungs are not a manufacturable organ like artificial heart valves or left ventricular assist devices, and since they are a limited resource compared to number of patients requiring the organs, the Department of Health and Human Services set the Final Rule of organ allocation in 1998. This led to development and implementation of Lung Allocation Score (LAS) in 2005. The score broadly divides lung diseases into 4 diagnostic criteria with a coefficient factor given to each category. The score is based on the prognostic factors of each patient to determine the risk of mortality without a transplant combined with the probability of patient survival post-transplant. Most of the guidelines for "Indications for referral and listing in lung transplant" is based on consensus opinion as there is limited amount of robust data and trials about this topic. The International Society for Heart and Lung Transplant (ISHLT) has published three editions for candidate selection and listing. In this article, we have attempted to highlight the guidelines and incorporated other disease specific prognostic factors that are not captured in the LAS. Ultimately, there are other factors like geographic location, height, blood group, preformed antibodies, transplant center experience, past wait times and transplant rate, availability of organs, etc., which also play a role especially when considering listing a patient for lung transplant. We also highlighted a representative disease in each category and most criteria for that disease will apply to other diseases in that category. Finally, this article does not delve into the history and reasoning behind each guideline but is meant to provide a general overview of indications and contraindications applicable in the field of adult lung transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.